Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report)’s stock price hit a new 52-week high on Wednesday . The stock traded as high as $382.54 and last traded at $371.67, with a volume of 309001 shares trading hands. The stock had previously closed at $378.15.
Analyst Ratings Changes
A number of research analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. HC Wainwright lifted their price objective on Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a report on Tuesday, June 16th. Citigroup boosted their target price on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Weiss Ratings downgraded Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday. Finally, TD Cowen raised their price target on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Ten analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Krystal Biotech presently has an average rating of “Moderate Buy” and a consensus target price of $340.56.
View Our Latest Analysis on Krystal Biotech
Krystal Biotech Trading Up 0.9%
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last announced its earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The company had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. On average, sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.66 EPS for the current year.
Insider Activity at Krystal Biotech
In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the sale, the insider owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This represents a 1.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the transaction, the executive vice president directly owned 1,000 shares of the company’s stock, valued at $347,270. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 26,642 shares of company stock valued at $8,243,923 over the last 90 days. Insiders own 13.10% of the company’s stock.
Institutional Trading of Krystal Biotech
Several institutional investors and hedge funds have recently made changes to their positions in KRYS. Sound Income Strategies LLC increased its position in Krystal Biotech by 1,270.0% during the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after purchasing an additional 127 shares in the last quarter. Western Wealth Management LLC acquired a new position in shares of Krystal Biotech in the first quarter valued at approximately $34,000. Greenline Wealth Management LLC acquired a new position in shares of Krystal Biotech in the fourth quarter valued at approximately $34,000. Danske Bank A S purchased a new position in shares of Krystal Biotech during the third quarter valued at approximately $35,000. Finally, UMB Bank n.a. lifted its stake in shares of Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after buying an additional 37 shares during the period. 86.29% of the stock is currently owned by hedge funds and other institutional investors.
About Krystal Biotech
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Read More
- Five stocks we like better than Krystal Biotech
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
